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Ghrelin modulates somatotroph, lactotroph, corticotroph,
and insulin secretion and glucose metabolism. To clarify the
influence of gender and age on the endocrine actions of
ghrelin in humans, we studied the effects of ghrelin (1.0 g/kg
iv) or placebo on GH, prolactin (PRL), ACTH, cortisol, insulin,
glucagon, and glucose levels in 18 young subjects (YS) and 16
elderly subjects (ES) of both genders. The GH response to
GHRH (1.0 g/kg iv) was also studied. The GH response to
ghrelin in YS was higher (P < 0.01) than in ES and both higher
(P < 0.01) than to GHRH, without gender-related differences.
In YS ghrelin also induced: 1) gender-independent increase
(P < 0.01) in PRL, ACTH, and cortisol levels; 2) gender-inde-
pendent increase in glucose levels (P < 0.01); 3) decrease (P <
0.01) in insulin levels in male YS; and 4) no change in glucagon.
In ES, ghrelin induced gender-independent PRL, ACTH, and
cortisol responses (P < 0.01). In ES ghrelin elicited gender-
independent transient decrease in insulin (P < 0.01) coupled
with increase in glucose levels (P < 0.05). In conclusion, the
GH-releasing effect of ghrelin is independent of gender but
undergoes age-related decrease. The effect of ghrelin on lac-
totroph and corticotroph secretion is age and gender inde-
pendent. In both ES and YS, ghrelin influences insulin secre-
tion and glucose metabolism. (J Clin Endocrinol Metab 88:
1537–1542, 2003)
IT IS WELL KNOWN that GH secretion varies as a functionof age and gender in humans (1, 2). The mechanisms
underlying the age-related changes in GH secretion certainly
include the influence of gonadal steroids and adiposity (1, 2).
However, there is evidence that the influence of aging on the
GH/IGF-I axis mainly reflects age-related changes in the
neuroendocrine control of GH secretion (1, 2). In fact, GH
secretion is primarily controlled by the central nervous sys-
tem, and it is mainly regulated by the tight interplay between
the hypothalamic neurohormones GHRH and somatostatin
with the cooperation of neurotransmitters, peripheral hor-
mones, and metabolic factors (1, 2).
The existence of another major unknown factor involved
in the control of somatotroph function had been hypothe-
sized on the basis of evidence that synthetic, nonnatural,
peptidyl, and nonpeptidyl molecules named GH secreta-
gogues (GHS) possess a strong GH-releasing effect acting on
the pituitary and mainly on the hypothalamus, in which
specific receptors (GHS-Rs) are present (3, 4). An endogenous
ligand for the GHS-R, named ghrelin, has recently been pu-
rified from both rat and human stomach (5). Ghrelin is a
28-amino acid peptide and shows a unique structure with an
n-octanoyl ester at its third serine residue that is essential for
its potent stimulatory activity on somatotroph secretion. An-
other ligand showing the same activity has been purified
from rat stomach; it is a 27-amino acid peptide named des-
Gln14-ghrelin, the sequence of which is identical to ghrelin
except for one glutamine (6). Brain ghrelin immunoreactive
neurons have also been localized in the hypothalamic arcuate
nucleus (3, 5–7).
Ghrelin specifically stimulates GH secretion in rats from
both pituitary cells in culture and in vivo (5, 6). Ghrelin
releases more GH than GHRH and even more than the syn-
thetic GHS hexarelin in humans; moreover, it synergizes
with GHRH but not with hexarelin (8–11). This evidence
agrees with the assumption that it exerts its effects via the
activation of the GHS-R at the pituitary and mainly at the
hypothalamic level, likely enhancing the activity of GHRH-
secreting neurons and also acting as functional somatostatin
antagonist (3, 4).
The GHS-R and its subtypes are not restricted to the
hypothalamus-pituitary unit but are also present in other
central and peripheral tissues (12, 13), and the activity of
ghrelin as well as of synthetic GHS is not fully specific for
GH. In fact, ghrelin stimulates lactotroph and corticotroph
secretion, has orexigenic activity and modulates energy bal-
ance also via influence on glucose metabolism and insulin
secretion, exerts cardiovascular actions, modulates cell pro-
liferation, and regulates gastric motility and acid secretion
through vagal mediation (3, 9, 11).
On the basis of studies with synthetic GHS, it had been
hypothesized that the hypoactivity of the natural ligand of
GHS-R could play a major role in the age-related changes of
somatotroph function (3, 14). In fact, synthetic GHS have
been shown able to induce considerable GH discharge in
elderly subjects, but their response is reduced with regard to
that in young adults (3, 15, 16). The age-related decrease in
Abbreviations: ES, Elderly subjects; GHS, GH secretagogue; GHS-R,
GHS-specific receptor; IRMA, immunoradiometric assay; PRL, prolac-
tin; YS, young subjects.
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the GH response to GHS had been surprisingly found un-
coupled to the reduction in both PRL- and ACTH-releasing
activity (17).
Because the endocrine activities of ghrelin as function of
age and gender have never been studied so far, in the present
study, we measured the GH, PRL, ACTH, cortisol, insulin,
glucagon, and glucose responses to acute iv ghrelin or pla-
cebo administration in normal young adults and elderly sub-
jects of both genders. The GH response to ghrelin was com-
pared with that of GHRH.
Subjects and Methods
Eighteen healthy young volunteers (YS) [nine males and nine females;
age (mean sd), 28.5 8.4 yr; body mass index, 22.7 3.0 kg/m2] and
16 normal elderly subjects (ES) (eight males and eight females; age,
71.4  8.1 yr; body mass index, 22.6  3.9 kg/m2) were studied. All
female YS were free of contraceptive therapy and were studied in their
early follicular phase; none of the female ES was on hormone replace-
ment therapy. All subjects gave their written informed consent to par-
ticipate in the study, which had previously been approved by the in-
dependent Ethical Committee of the University of Turin.
All subjects underwent the following three testing sessions in random
order and at least 3 d apart: 1) placebo (2 ml isotonic saline iv at 0 min);
2) ghrelin (1.0 g/kg iv at 0 min); and 3) GHRH-29 (1.0 g/kg iv at 0
min).
After overnight fasting, the tests were begun in the morning at 0830–
0900 h, 30 min after an indwelling catheter had been inserted in an
anterocubital vein of the forearm kept patent by slow infusion of isotonic
saline.
Blood samples were taken every 15 min from15 up to90 min. GH
levels were assayed at each time point in all sessions; prolactin (PRL),
ACTH, cortisol, insulin, glucagon, and glucose levels were also assayed
after placebo or ghrelin administration.
Serum GH levels (micrograms per liter; 1 g/liter 45.4 pmol/liter)
were measured in duplicate by immunoradiometric assay (IRMA)
(hGH-CTK, IRMA, SORIN Biomedica, Saluggia, Italy). The sensitivity of
the assay was 0.15 g/liter. The inter- and intra-assay variation coef-
ficients were 2.9–4.5% and 2.4–4.0%, respectively.
Serum PRL levels (micrograms per liter; 1 g/liter 43.5 pmol/liter)
were measured in duplicate by IRMA (PRL-CTK, IRMA, SORIN Bio-
medica). The sensitivity of the assay was 0.15 g/liter. The inter- and
intra-assay variation coefficients ranged between 3.9% and 6.8% and
between 3.3% and 7.5%, respectively.
Plasma ACTH levels (picograms per milliliter; 1 pg/ml  0.2202
pmol/liter) were measured in duplicate by IRMA (Allegro HS-ACTH,
Nichols Institute Diagnostic, San Juan Capistrano, CA). The sensitivity
of the assay was 1 pg/ml. The inter- and intra-assay variation coeffi-
cients ranged between 2.4% and 8.9% and between 3.9% and 9.9%,
respectively.
Serum cortisol levels (micrograms per liter; 1 g/liter 2.759 nmol/
liter) were measured in duplicate by RIA (CORT-CTK 125, IRMA,
SORIN Biomedica). The sensitivity of the assay was 4.0 g/liter. The
inter- and intra-assay variation coefficients ranged between 6.6% and
7.5% and between 3.8% and 6.6%, respectively.
Serum insulin levels (milliunits per liter; 1 mU/liter  7.175 pmol/
liter) were measured in duplicate by IRMA (INSIK-5, SORIN Bio-
medica). The sensitivity of the assay was 2.5  0.3 mU/liter. The inter-
and intra-assay coefficients of variation were 6.2–10.8% and 5.5–10.6%,
respectively.
Plasma glucagon levels (micrograms per liter; 1 g/liter  3.57142
pmol/liter) were measured by IRMA (GLUCAGON, Biochem Immu-
nosystems, Guidonia Montecelio, Italy). The sensitivity of the assay was
14.5 g/liter. The inter- and intra-assay coefficients of variation were
8.2–9.0% and 8.0–9.5%, respectively.
Plasma glucose levels (milligrams per deciliter; 1 mg/dl  0.05551
mmol/liter) were measured by glucooxidase colorimetric method
(GLUCOFIX, Menarini Diagnostici, Florence, Italy).
All samples from an individual subject were analyzed together. The
hormonal responses are expressed as mean  sd  changes vs. baseline
and  areas under curves calculated by trapezoidal integration. The T
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statistical analysis was carried out using nonparametric ANOVA (Fried-
man test) and then Mann-Whitney U test as appropriate.
Results
No significant changes in GH, PRL, insulin, and glucose
levels were observed after placebo administration both in YS
and ES of both genders. On the other hand, a significant (P
0.05) trend toward decrease of spontaneous ACTH, cortisol,
and glucagon levels was observed.
In YS ghrelin induced strong GH increase, which was
similar in both genders (Table 1 and Fig. 1).
The GH response to ghrelin was markedly higher (P 
0.01) than that induced by GHRH in YS in both males (mean
 change vs. baseline, 13.7  8.7 g/liter;  areas under
curves, 1383.9 1204.2 gmin/liter) and females (11.8 8.4
g/liter; 1212.1  502.1 gmin/liter) (Fig. 1).
The GH responses to ghrelin in male and female ES were
similar and both lower (P  0.05) than those in male and
female YS (Table 1 and Fig. 1).
The GH responses to GHRH in male (4.0  2.2 g/liter;
397.5  271.6 gmin/liter) and female (2.3  1.5 g/liter;
230.5 227.6 gmin/liter) ES subjects were lower (P 0.01)
than those in YS as well as those induced by ghrelin in ES (P
0.01) (Fig. 1).
In YS ghrelin also induced: 1) a significant (P  0.01)
increase in PRL, ACTH, and cortisol levels, which was sim-
ilar in both genders (Table 1 and Fig. 2); 2) a gender-inde-
pendent increase (P  0.05) in glucose levels (Table 1 and
Fig. 3); 3) a significant decrease (P 0.01) in insulin levels in
young men only (Table 1 and Fig. 3); and 4) no change in
glucagon levels (Table 1).
In ES the ghrelin-induced increase (P 0.01) in PRL levels
was similar to that in YS, without significant differences
between males and females (Table 1 and Fig. 2).
Similarly, the ACTH and cortisol responses (P  0.01) to
ghrelin in ES were similar to those in YS and independent of
gender (Table 1 and Fig. 2).
Moreover, in ES ghrelin administration elicited gender-
independent transient decrease in insulin levels (P  0.01),
which was coupled with significant increase in glucose levels
(P  0.05) (Table 1 and Fig. 3).
Side effects
A transient facial flushing was observed after administra-
tion of GHRH in six subjects. Twelve subjects sensed a pe-
culiar sudden increase in appetite directly following ghrelin
administration.
Discussion
The results of the present study demonstrate that: 1) the
GH-releasing effect of ghrelin is independent of gender but
undergoes an age-related decrease; 2) the stimulatory effect
of ghrelin on lactotroph and corticotroph secretion is inde-
pendent of either gender or age; and 3) acute ghrelin ad-
ministration increases glucose levels coupled with inhibitory
influence on insulin secretion independently of age.
That acute administration of acylated ghrelin induces
strong increase in GH secretion coupled with significant
increase in lactotroph and corticotroph secretion (9, 11) as
well as hyperglycemic effect coupled with transient insulin
decrease (18) had already been shown in normal adult vol-
unteers. This is the first study describing the endocrine re-
sponse to ghrelin in humans in both genders in YS and ES.
The lack of gender-related difference in the GH response
to ghrelin in YS and ES agrees with similar findings obtained
studying the effects of synthetic GHS throughout life (3, 19).
At puberty only, the GH response to GHS has been reported
higher in females than in males, and an enhancing effect of
pharmacological doses of estrogens on the GH response to
GHS in postmenopausal women has been reported by some
but not by other authors (3, 20–22). In fact, hypothalamic
GHS receptor expression is modulated by estradiol (23). Our
present findings showing that the GH response to ghrelin is
independent of gender in YS and ES suggest that changes in
estrogen milieu in adulthood do not affect the somatotroph
response to this gastric hormone. The possibility that expo-
sure to pharmacological levels of estrogens might affect the
somatotroph response to ghrelin remains to be verified.
Our present data also fully agree with previous findings
from studies with synthetic GHS showing that even the stim-
ulator effect of ghrelin on either lactotroph or corticotroph
FIG. 1. Mean (SD)  GH responses to acute ghrelin (1.0 g/kg iv at 0 min) or GHRH (1.0 g/kg iv at 0 min) administration in young or elderly
male and female normal subjects.
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secretion is gender independent and therefore unlikely de-
pendent on the estrogenic milieu (3).
As opposed to no dependence on gender, the GH response
to ghrelin shows clear age-related decrease in both genders.
This evidence agrees with previous findings showing that
the GH response to either peptidyl or nonpeptidyl synthetic
GHS in ES of both genders is lower than in adult subjects (3,
15, 16). Anyway, it has also to be considered that, theoreti-
cally, although a more frequent sampling would have pro-
vided more details in terms of qualitative description of the
secretory events, no substantial different information in terms
of integrated quantitative amount of hormone secreted would
have been obtained by simply increasing sampling frequency.
Actually, the absolute mean GH response to ghrelin (in the
present study) as well as to synthetic GHS in ES was remark-
able in agreement with the availability of almost preserved
GH-releasable pool in the aged pituitary (3). This evidence
was also the rational basis to hypothesize that chronic treat-
ment with orally active GHS in aging would rejuvenate the
function of the GH/IGF-I axis (15, 24). The age-related
decrease of the GH response to ghrelin and GHS agrees with
the well known in vitro and in vivo hyporesponsiveness of
the aged somatotroph cells to the majority of provocative
stimuli, including GHRH, despite the availability of remark-
able GH-releasable pool (1–3).
It has been clearly shown that the age-related reduction of
both spontaneous and stimulated GH secretion reflects age-
related changes in the neural control of somatotroph function
(1, 2). These changes include concomitant reduction in
GHRH and enhancement in somatostatin activity (1, 2) that
would per se explain the reduced response to ghrelin and
GHS in aging. In fact, the GH-releasing activity of natural
and synthetic GHS depends on the functional integrity of the
hypothalamus-pituitary unit and in particular GHRH-secret-
ing neurons (3).
However, somatotroph insufficiency in aging would also
reflect some impairment in the ghrelin/GHS system. In fact,
GHS-R expression has been found reduced in the aged human
hypothalamus in both genders (3). This would further explain
the reduced GH response to ghrelin in ES of both genders.
FIG. 2. Mean (SD)  PRL, ACTH, and cortisol changes vs. baseline
after acute ghrelin (1.0 g/kg iv) administration in young or elderly
male and female normal subjects.
FIG. 3. Mean (SD)  insulin and glucose changes vs. baseline after
acute ghrelin (1.0 g/kg iv) administration in young or elderly male
and female normal subjects.
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At variance with the influence of age on the stimulatory
effect of ghrelin on somatotroph secretion, we found that its
stimulatory effect on lactotroph and corticotroph secretion is
independent of age. The lack of any influence of aging on the
PRL- and ACTH-releasing activity of ghrelin replicates what
had been found studying the effects of synthetic GHS (17)
and is intriguing. In fact, the PRL-releasing activity of GHS
more likely depends on direct pituitary action, but the
ACTH-releasing activity is totally dependent on actions at
the central nervous system level only, partially involving
CRH- and/or arginine vasopressin-mediated mechanisms (3).
Evidence that the ghrelin-induced PRL release does not vary
with age indicates that the PRL-releasing activity is not medi-
ated by estrogens and dopaminergic tone that play a major role
in age-dependent changes of lactotroph function (25).
On the other hand, the age independence of the stimula-
tory effect of ghrelin on corticotroph secretion agrees with
evidence that the ACTH-releasing activity of ghrelin as well
as synthetic GHS is not mediated by CRH-mediated mech-
anisms (3). In fact, both spontaneous and CRH-stimulated
ACTH secretion are reported increased in aging, probably as
a consequence of altered sensitivity to glucocorticoid feed-
back at the hippocampal level (26).
The age-related dissociation between the stimulatory ef-
fect of ghrelin on somatotroph cells on one hand and on
lactotroph and corticotroph cells on the other hand suggests
that ghrelin acts at different levels and/or on different re-
ceptor subtypes to modulate these pituitary hormonal se-
cretions; moreover, this evidence makes unlikely the possi-
bility that the age-related differences in the GH-responses to
ghrelin might be due to different ghrelin half-lives during the
lifespan, although further studies to describe ghrelin kinetic
are needed to definitely rule out this possibility.
With regard to the impact of ghrelin on glucose and insulin
levels in humans, it had already been shown that ghrelin, but
not hexarelin, a synthetic peptidyl GHS, has hyperglycemic
effect coupled with transient inhibition of insulin secretion in
normal male adults (18). Our present findings confirm these
effects of ghrelin in humans and show that they are basically
independent of both gender and age, although in the present
study, young women did not show significant change in
insulin levels following ghrelin administration.
The functional relationship between ghrelin and insulin is
still unclear, although ghrelin and GHS-R expression have
been demonstrated in the endocrine pancreas either in ani-
mals and humans (3, 13, 27, 28). There is clear negative
association between insulin and ghrelin secretion (29), and
insulin has been reported able to decrease ghrelin secretion
in humans (30). Actually, ghrelin has been found able to inhibit
or stimulate insulin secretion, depending on different experi-
mental conditions in animals (28, 31–33). The hypothetical ex-
istence of a functional feedback mechanism linking ghrelin and
insulin secretion has, therefore, to be taken into account.
The transient inhibitory effect of ghrelin on insulin levels
is coupled with significant increase in glucose levels that is
apparent independent of either age or gender. This rise in
glucose levels would be unrelated to insulin decrease be-
cause often this follows the hyperglycemic effect, at least
when evaluated in the general circulation. We show here that
rise in plasma glucose levels is not reflecting increase in
glucagon secretion that, in fact, was unchanged after ghrelin
administration in YS as well as ES. Thus, to explain the
hyperglycemic effect of ghrelin, a direct glycogenolitic effect
at the hepatic level would be hypothesized, and it would
likely occur via a GHS-R non-type 1a receptor because syn-
thetic, peptidyl GHS do not affect glucose levels (18).
In conclusion, this study shows that the GH-releasing ef-
fect of ghrelin is independent of gender but undergoes age-
related decrease. On the other hand, the stimulatory effect of
ghrelin on lactotroph and corticotroph secretion is indepen-
dent of either age or gender. Ghrelin shows influence on
insulin secretion and glucose metabolism in ES as well as YS.
These findings further indicate that ghrelin is not simply a
natural GHS but has a wide spectrum of endocrine actions
that are variably dependent on age and gender.
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